- Report
- September 2022
- 76 Pages
Brazil
From €3001EUR$3,350USD£2,558GBP
- Report
- September 2022
- 77 Pages
France
From €3001EUR$3,350USD£2,558GBP
- Report
- September 2022
- 75 Pages
Germany
From €3001EUR$3,350USD£2,558GBP
- Report
- May 2023
- 92 Pages
North America
From €1344EUR$1,500USD£1,145GBP
- Report
- April 2024
- 45 Pages
Global
From €8952EUR$9,995USD£7,631GBP
- Report
- December 2023
- 295 Pages
Global
€4474EUR$4,995USD£3,814GBP
- Report
- August 2024
- 238 Pages
China
From €3583EUR$4,000USD£3,054GBP
- Report
- June 2024
- 211 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- June 2024
- 200 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- July 2023
- 200 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- January 2025
- 135 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- August 2024
- 104 Pages
China
From €1612EUR$1,800USD£1,374GBP
The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers.
Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more
